Over the past few years, the prognosis of patients with advanced melanoma has been improved by the use of programmed cell death antibody 1 (PD-1), anti-cytotoxic antibody protein 4 associated with T-lymphocytes (CTLA-4), BRAF inhibitors, and MEK inhibitors [8]. Here, MAP2K7 is linked to melanoma.